Please login to the form below

Not currently logged in
Email:
Password:

Synairgen

This page shows the latest Synairgen news and features for those working in and with pharma, biotech and healthcare.

UK biotech Synairgen to begin COVID-19 trial of lead candidate

UK biotech Synairgen to begin COVID-19 trial of lead candidate

Southampton, UK-based biotech company Synairgen has been granted the go-ahead to take its lead candidate SNG001 into a trial for the treatment of COVID-19 patients. ... It’s fantastic to see a small UK biotech company, Synairgen starting UK clinical

Latest news

  • AZ severe asthma drug benralizumab backed by CHMP AZ severe asthma drug benralizumab backed by CHMP

    Last year AZ's respiratory pipeline suffered another setback after the company halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma, deciding it was

  • Setback for AZ as tralokinumab flunks asthma trial Setback for AZ as tralokinumab flunks asthma trial

    Last year AZ's respiratory pipeline suffered another setback after the company halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma, deciding it was

  • AZ trial adds to pessimism about anti-IL-13 asthma drugs AZ trial adds to pessimism about anti-IL-13 asthma drugs

    Last year AZ's respiratory pipeline took a further knock when it halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma after deciding it

  • Synairgen sinks as AZ halts trial of asthma drug Synairgen sinks as AZ halts trial of asthma drug

    AZD9412 is an inhaled form of interferon beta partnered with UK company Synairgen, which saw its London Stock Exchange-listed shares lose more than a third of their value yesterday when ... For Synairgen, the setback lends greater importance to its

  • AZ licenses asthma infection drug from Synairgen AZ licenses asthma infection drug from Synairgen

    Boosts respiratory portfolio with $232m deal. AstraZeneca (AZ) has added to its portfolio of respiratory drug candidates after licensing an inhaled interferon beta therapy from Synairgen which is in trials to ... AZ is paying UK-based Synairgen $7.25m

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics